It’s no simple task for a biotech giant to try to sell itself to investors as a value stock. That has been the case for some time when it comes to Gilead…
Jon C. Ogg The April 15 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how…
Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value going forward.
The March 29 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Gilead Sciences, Nordstrom, Novartis, Tesla, Under Armour, Walt Disney and Wendy's.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The February 15 short interest data have been compared with the previous report, and short interest in most…
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The January 31 short interest data have been compared with the previous report, and short interest in most…
It's another disappointing day for one of America's top biotech companies. But that may prove to be great news for Intercept Pharmaceuticals.
Jon C. Ogg The top analyst upgrades, downgrades and initiations seen on Tuesday included BHP, Cisco Systems, Crown Castle, Gilead Sciences, Goldcorp, Take-Two Interactive Software, Varonis Systems and Whiting Petroleum.
Gilead Sciences is living up to our theory that Big Biotech is now effectively the same as Big Pharma.
Jon C. Ogg 24/7 Wall St. has reviewed Disney, General Motors, Twitter and some of the other key stocks reporting earnings this coming week.
There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options for devices,…
